Home/Pipeline/Anti-IgE program (Excellergy)

Anti-IgE program (Excellergy)

Allergic Diseases

Pre-clinicalAcquisition AnnouncedN/A

Key Facts

Indication
Allergic Diseases
Phase
Pre-clinical
Status
Acquisition Announced
Company

About Novartis

Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.

View full company profile

Other Allergic Diseases Drugs

DrugCompanyPhase
Allergy Service & Product ExpansionBio-DiagnosticsCommercial